Fibro Daily

Zohydro ER Set for FDA Review

Fibro Daily December 6, 2012

The potential for abuse as well as overdosing on the opioid Zohydro ER is high, so the Food and Drug Administration (FDA) is set to review that potential.

Although the drug did meet certain efficacy requirements, many medical professionals worry about its use. Lori Love, MD, PhD, and medical officer of the FDA’s Controlled Substance Staff said, “If approved and marketed, Zohydro ER will be abused, possibly at a rate greater than that of currently available hydrocodone combination products.”

Read more:

FDA Panel to Review Opioid



Powered by Facebook Comments

Tagged with:

Comments are closed.

Login to your account

Can't remember your Password ?

Register for this site!